Abiopharma

New Form F-1/A - IceCure Medical Ltd. Filed: 2025-06-25 AccNo: 0001213900-25-057495 Size: 1 MB

Lifeward Announces Pricing of $2.6 Million Public Offering

Quest Diagnostics Releases 2024 Corporate Responsibility Report

Methodist Hospitals Selects Philips to Advance Neurovascular, Cardiology and Complex Interventional Radiology Services in Northwest Indiana

New Form 4 - MESA LABORATORIES INC /CO/ Filed: 2025-06-25 AccNo: 0001228924-25-000017 Size: 8 KB

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Akari Therapeutics Releases Virtual Investor“What This Means” Segment Highlighting its Recently Granted India Patent

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

New Form 8-K - ZyVersa Therapeutics, Inc. Filed: 2025-06-25 AccNo: 0001641172-25-016388 Size: 674 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 4 - Silence Therapeutics plc Filed: 2025-06-25 AccNo: 0001104659-25-062407 Size: 9 KB

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

FDA Grants RMAT Designation for enGenes Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

New Form 8-K - Quoin Pharmaceuticals, Ltd. Filed: 2025-06-25 AccNo: 0001104659-25-062406 Size: 188 KB Item 8.01: Other Events

New Form 8-K - Glucotrack, Inc. Filed: 2025-06-25 AccNo: 0001641172-25-016387 Size: 245 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Silo Pharma Notification (SILO)